Pharmaceuticals

Global Next Generation Tissue Biomarkers Market Report 2026–2030: Data-Driven Growth Insights

February 17, 2026February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the next generation tissue biomarkers market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Next Generation Tissue Biomarkers Market’s size between 2026 and 2030?

The next generation tissue biomarkers market size has shown rapid growth in recent years. It is projected to expand from $3.03 billion in 2025 to $3.42 billion in 2026, at a compound annual growth rate (CAGR) of 12.9%. The market’s historic growth can be attributed to several factors including reliance on traditional histopathology techniques, limitations in biomarker identification methods, increasing oncology research, the rising adoption of companion diagnostics, and early-stage investment in genomic and proteomic studies.

The next generation tissue biomarkers market size is projected to experience substantial expansion over the next several years. This market is expected to reach $5.51 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.6%. This anticipated growth during the forecast period is driven by improvements in next-generation sequencing technologies, the incorporation of AI-based tissue analysis, the spread of spatial biology platforms, increasing investment in multi-omics research, and stronger collaborations between pharmaceutical companies and academic institutes. Prominent trends for this period encompass the wider application of spatial biology and multi-omics approaches, greater adoption of digital pathology and AI analysis in diagnostics, an increasing requirement for biomarkers in oncology and companion diagnostics, enhanced drug discovery and development utilizing tissue biomarkers, and the integration of transcriptomic and metabolomic biomarkers to advance precision medicine.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27363&type=smp

Which Drivers Are Shaping Strategic Decisions In The Next Generation Tissue Biomarkers Market?

The increasing need for tailored medical treatments is anticipated to fuel the expansion of the next generation tissue biomarkers market moving forward. Personalized medicine customizes therapies by considering a person’s unique genetic characteristics, lifestyle, and environmental influences. Its adoption is on the rise, driven by ongoing progress in genomic technologies that enable highly specific and individualized treatment plans. This heightened demand for personalized medicine, in turn, stimulates the creation of next-generation tissue biomarkers, which offer the accurate and custom data essential for adapting treatments to each patient’s distinct tissue profile. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit, reported that the FDA cleared 16 new personalized therapies for patients with rare diseases in 2023, a significant increase from 6 in 2022. Among the personalized treatments approved in 2023 were also seven drugs targeting cancer and three for other conditions. Consequently, the growing requirement for personalized medicine is a key factor propelling the development of the next generation tissue biomarkers market.

What Segment Categories Are Covered In The Next Generation Tissue Biomarkers Market?

The next generation tissue biomarkers market covered in this report is segmented –

1) By Type: Genomic Biomarkers, Proteomic Biomarkers, Epigenetic Biomarkers, Transcriptomic Biomarkers, Metabolomic Biomarkers

2) By Technology: Immunohistochemistry, Next-Generation Sequencing, Mass Spectrometry (Ms)-Based Proteomics, Spatial Biology Platforms, Digital Pathology And Artificial Intelligence Analysis, Other Technologies

3) By Application: Oncology, Companion Diagnostics, Drug Discovery And Development, Neurology, Other Applications

4) By End Use: Hospitals And Reference Labs, Pharma And Biotech Companies, Academic And Research Institutes, Contract Research Organizations

Subsegments:

1) By Genomic Biomarkers: Single Nucleotide Polymorphisms, Copy Number Variations, Gene Fusions

2) By Proteomic Biomarkers: Protein Expression Levels, Post-Translational Modifications, Protein-Protein Interactions

3) By Epigenetic Biomarkers: Histone Modification Patterns, Chromatin Remodeling Biomarkers, Non-Coding Ribonucleic Acid Regulation

4) By Transcriptomic Biomarkers: Long Non-Coding Ribonucleic Acids, Circular Ribonucleic Acids, Alternative Splicing Variants

5) By Metabolomic Biomarkers: Lipid Profiles, Amino Acid Signatures, Organic Acids

Which Trends Are Influencing The Development Of The Next Generation Tissue Biomarkers Market?

Leading companies within the next generation tissue biomarkers market are concentrating on developing advanced solutions, such as genomic-based diagnostic assays and sequencing technologies, aimed at enhancing the precision, speed, and customization of cancer diagnosis and treatment. These genomic diagnostic assays and sequencing solutions are defined as tools and methods that examine genetic information to identify disease-related biomarkers, thereby enabling more exact and individualized strategies for diagnosis and therapy. For example, in August 2024, Illumina Inc., a US-based biotechnology company, obtained FDA approval for its TruSight Oncology Comprehensive test, alongside two companion diagnostics, designed to quickly connect cancer patients with targeted treatments. The test evaluates over 500 genes from a single tissue sample, allowing for accurate therapy selection across various solid tumors. It automates biomarker detection and supports 24/7 deployment, substantially decreasing turnaround times and improving clinical efficiency, which signifies a modern strategy for optimizing cancer diagnostics within a regulated environment.

Which Key Players Are Driving Competition In The Next Generation Tissue Biomarkers Market?

Major companies operating in the next generation tissue biomarkers market are Roche Diagnostics, Thermo Fisher Scientific Inc., LabCorp., Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Bio-Techne Corporation, Myriad Genetics Inc., NeoGenomics Laboratories Inc., Foundation Medicine Inc., NanoString Technologies Inc., PathAI Inc., Biocartis Group NV, Personalis Inc., Ultivue Inc., Indica Labs Inc., Strata Oncology Inc., Genialis Inc., Alida Biosciences Inc., Biofidelity Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/next-generation-tissue-biomarkers-global-market-report

Which Region Is Projected To Lead The Next Generation Tissue Biomarkers Market During The Forecast Period?

North America was the largest region in the next generation tissue biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation tissue biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Next Generation Tissue Biomarkers Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27363&type=smp

Browse Through More Reports Similar to the Global Next Generation Tissue Biomarkers Market 2026, By The Business Research Company

Nail Care Products Market Report 2026

https://www.thebusinessresearchcompany.com/report/nail-care-products-global-market-report

Nail Salon Market Report 2026

https://www.thebusinessresearchcompany.com/report/nail-salon-global-market-report

Nail Polish Market Report 2026

https://www.thebusinessresearchcompany.com/report/nail-polish-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795